Ketamine for complex cancer pain

A randomised, double-blind, placebo-controlled study of subcutaneous ketamine in the management of cancer pain

DOI10.58084/xcp3-4d44
Type of DOIdataset
PublisherCancer Symptom Trials (CST)
Creator(s)Janet Hardy, Mater Adult Hospital
Date made available2023
Description of dataset

Dataset includes:

  • data for 185 participants with pain caused by cancer (93 allocated to Ketamine, 92 allocated to placebo)
  • treatment period over 5 days, with follow-up for 4 weeks post treatment
  • data available for demographic data
  • primary outcome as Brief Pain Inventory score
  • quality of life (as EORTC QLQ -C30 and FACIT-PAL)
  • performance status (as AKPS)
  • opioid use
  • Global Impression of Change
  • adverse events (as NCI CTCAE V3.0)
  • carer QOL (as Caregiver QOLC)
  • Medicare Australia data, and
  • survival
Funding 
Subject (ANZSRC category)Clinical sciences (pain)
ANZCTR referenceACTRN12607000501448
Main trial pageCST clinical trials
Publications

Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain

Economic evaluation of the randomised, double-blind, placebo-controlled study of subcutaneous ketamine in the management of chronic cancer pain

Can the LANSS scale be used to classify pain in chronic cancer pain trials?

Dataset accessAccess can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with these trials or email enquiries to hesanda@uts.edu.au.

 

Acknowledgement of Country

UTS acknowledges the Gadigal people of the Eora Nation, the Boorooberongal people of the Dharug Nation, the Bidiagal people and the Gamaygal people, upon whose ancestral lands our university stands. We would also like to pay respect to the Elders both past and present, acknowledging them as the traditional custodians of knowledge for these lands.